Hims & Hers Retreats on Cheap Wegovy Pill Amid Legal Firestorm

David Ostrowsky explores Hims & Hers’ brief attempt to introduce a low-cost, compounded alternative to Wegovy and the immediate legal backlash that forced the company to retreat. He dives into how patent protections, FDA regulations, and increased scrutiny of compounded GLP-1 drugs are shaping the competitive landscape for weight-loss medications. In addition, he considers what this conflict signals for employers, plan sponsors, and the broader healthcare market as demand for more affordable treatment options continues to rise amid tightening regulatory oversight.